Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Donahue

Family Medicine Adel, IA Doctor of Osteopathy

NPI 1891797445 CMS profile 86001

710 Common Pl Ste 700, Adel, IA 50003

Open in the dashboard

General payments

$4,287

289 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Donahue of Adel, IA is reported in the CMS Open Payments database as having received $4,287 across 289 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $320 17
2024 General $657 45
2023 General $720 53
2022 General $897 57
2021 General $612 41
2020 General $503 41
2019 General $579 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Donahue
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Susan Donahue were reported at $320. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Susan Donahue Family Medicine median Middle half National median
2019 $579 $150 $41–$543 $163
2020 $503 $120 $32–$415 $114
2021 $612 $137 $35–$551 $132
2022 $897 $137 $37–$512 $149
2023 $720 $149 $42–$545 $160
2024 $657 $156 $44–$560 $164
2025 $320 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $816 66 payments
  2. Allergan Inc. $383 31 payments
  3. Lilly USA, LLC $299 16 payments
  4. Sumitomo Pharma America, Inc. $274 23 payments
  5. Sunovion Pharmaceuticals Inc. $245 21 payments
  6. Novo Nordisk Inc $224 14 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $222 12 payments
  8. Pfizer Inc. $205 11 payments
  9. Novartis Pharmaceuticals Corporation $186 12 payments
  10. Amgen Inc. $181 12 payments
  11. Other $1,254 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,257 287 payments
  2. Education $31 2 payments
Products named General payments · program years 2019–2025
  1. GEMTESA $506 43 payments
  2. UBRELVY Neuroscience $472 37 payments
  3. QULIPTA $372 27 payments
  4. VRAYLAR $171 17 payments
  5. UBRELVY Neuroscience $156 17 payments
  6. Ozempic $148 9 payments
  7. SPIRIVA RESPIMAT $137 9 payments
  8. Repatha $136 10 payments
  9. NATRELLE $122 1 payment
  10. REXULTI $119 6 payments
  11. Other $3,057 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 137 drugs

Part D claims

9,235

Median for Family Practice: 1,826

Drug cost

$715,110

Median for Family Practice: $120,094

Branded share of claims

17.3%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 159 $195,153
Eliquis Apixaban Brand 102 $72,003
Jardiance Empagliflozin Brand 92 $60,805
Mounjaro Tirzepatide Brand 54 $52,711
Tresiba Flextouch U-200 Insulin Degludec Brand 45 $52,043
Gemtesa Vibegron Brand 35 $26,057
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $25,883
Xarelto Rivaroxaban Brand 24 $24,543
Januvia Sitagliptin Phosphate Brand 24 $17,670
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 26 $14,700

The 10 drugs with the highest cost, of 137 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$161,881

Of which drugs: $11,405

Medicare patients

348

Average age 75

Services billed

5,610

234 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 37%
Diabetes 26%
Ischemic heart disease 20%
Chronic kidney disease 20%
Depression 19%
Osteoporosis 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 22 22 $6,398
Vaccine for influenza for injection into muscle 90662 Office 57 58 $4,676

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $91
$91 — —
UBRELVY
  • AbbVie, Inc. $77
$77 — —
QULIPTA
  • AbbVie, Inc. $69
$69 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $58
$58 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record